Bioeq IP AG

Formycon continues to secure launches in global markets for its ranibizumab biosimilar FYB201 as the German firm introduces the Lucentis rival in Canada and Switzerland, where it will be marketed as

A change in the US Food and Drug Administration’s scientific thinking led Amgen, Inc. to request an interchangeability designation for Wezlana, a biosimilar of Janssen Biotech Inc. ’s Stelara (uste

Formycon AG has announced Health Canada approval for its Ranopto (ranibizumab) biosimilar for the treatment of serious retinal diseases, adding to the company’s growing roster of approvals for the pr

Interchangeable biosimilars can be substituted for reference products without the intervention of a prescribing healthcare provider, but that doesn’t imply better safety or effectiveness than other ap